Prevents delayed nausea and vomiting associated with initial and repeat courses of…. Sold as Varubi. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Rolapitant Hydrochloride (sold as Varubi), first approved Sep 1, 2015, with 0 new uses approved and 0 published complete response letters.
| Varubi | Part D | $377K | -29% | 153 |
| Varubi | Part B | $9K | -5% | 0 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and PalonosetronLung Cancer · Henan Cancer Hospital | Not applicable | Not yet recruiting | Mar 2, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
